Literature DB >> 33004426

Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review.

David Jarrom1, Lauren Elston2, Jennifer Washington2, Matthew Prettyjohns2, Kimberley Cann2,3, Susan Myles2, Peter Groves2.   

Abstract

OBJECTIVES: We undertook a rapid systematic review with the aim of identifying evidence that could be used to answer the following research questions: (1) What is the clinical effectiveness of tests that detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to inform COVID-19 diagnosis? (2) What is the clinical effectiveness of tests that detect the presence of antibodies to the SARS-CoV-2 virus to inform COVID-19 diagnosis? DESIGN AND
SETTING: Systematic review and meta-analysis of studies of diagnostic test accuracy. We systematically searched for all published evidence on the effectiveness of tests for the presence of SARS-CoV-2 virus, or antibodies to SARS-CoV-2, up to 4 May 2020, and assessed relevant studies for risks of bias using the QUADAS-2 framework. MAIN OUTCOME MEASURES: Measures of diagnostic accuracy (sensitivity, specificity, positive/negative predictive value) were the main outcomes of interest. We also included studies that reported influence of testing on subsequent patient management, and that reported virus/antibody detection rates where these facilitated comparisons of testing in different settings, different populations or using different sampling methods.
RESULTS: 38 studies on SARS-CoV-2 virus testing and 25 studies on SARS-CoV-2 antibody testing were identified. We identified high or unclear risks of bias in the majority of studies, most commonly as a result of unclear methods of patient selection and test conduct, or because of the use of a reference standard that may not definitively diagnose COVID-19. The majority were in hospital settings, in patients with confirmed or suspected COVID-19 infection. Pooled analysis of 16 studies (3818 patients) estimated a sensitivity of 87.8% (95% CI 81.5% to 92.2%) for an initial reverse-transcriptase PCR test. For antibody tests, 10 studies reported diagnostic accuracy outcomes: sensitivity ranged from 18.4% to 96.1% and specificity 88.9% to 100%. However, the lack of a true reference standard for SARS-CoV-2 diagnosis makes it challenging to assess the true diagnostic accuracy of these tests. Eighteen studies reporting different sampling methods suggest that for virus tests, the type of sample obtained/type of tissue sampled could influence test accuracy. Finally, we searched for, but did not identify, any evidence on how any test influences subsequent patient management.
CONCLUSIONS: Evidence is rapidly emerging on the effectiveness of tests for COVID-19 diagnosis and management, but important uncertainties about their effectiveness and most appropriate application remain. Estimates of diagnostic accuracy should be interpreted bearing in mind the absence of a definitive reference standard to diagnose or rule out COVID-19 infection. More evidence is needed about the effectiveness of testing outside of hospital settings and in mild or asymptomatic cases. Implementation of public health strategies centred on COVID-19 testing provides opportunities to explore these important areas of research. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  evidence-based practice; health services research; infectious disease medicine; public health; respiratory tract infections

Mesh:

Substances:

Year:  2020        PMID: 33004426     DOI: 10.1136/bmjebm-2020-111511

Source DB:  PubMed          Journal:  BMJ Evid Based Med        ISSN: 2515-446X


  26 in total

1.  The detection dogs test is more sensitive than real-time PCR in screening for SARS-CoV-2.

Authors:  Yasser Mahmmod; Rashid Manzoor; Mohammed Hag-Ali; Abdul Salam AlShamsi; Linda Boeijen; Harry Rutten; Marshal M Mweu; Mohamed El-Tholoth; Abdullatif Alteraifi AlShamsi
Journal:  Commun Biol       Date:  2021-06-03

2.  Perspective: Did Covid-19 Change Non-small Cell Lung Cancer Surgery Approach?

Authors:  Paola Ciriaco; Angelo Carretta; Alessandro Bandiera; Piergiorgio Muriana; Giampiero Negri
Journal:  Front Surg       Date:  2021-05-12

3.  Reply.

Authors:  F Bala; J Siddiqui; S Sciacca; A M Falzon; M Benger; S A Matloob; F N A C Miller; R J Simister; I Chatterjee; L K Sztriha; I Davagnanam; T C Booth
Journal:  AJNR Am J Neuroradiol       Date:  2021-05-20       Impact factor: 4.966

Review 4.  Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review.

Authors:  Salvatore Annunziata; Roberto C Delgado Bolton; Christel-Hermann Kamani; John O Prior; Domenico Albano; Francesco Bertagna; Giorgio Treglia
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-10

5.  Performance of two rapid point of care SARS-COV-2 antibody assays against laboratory-based automated chemiluminescent immunoassays for SARS-COV-2 IG-G, IG-M and total antibodies.

Authors:  C S Lau; S P Hoo; Y L Liang; S K Phua; T C Aw
Journal:  Pract Lab Med       Date:  2021-01-19

6.  Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center.

Authors:  Permesh Singh Dhillon; Robert A Dineen; Haley Morris; Radu Tanasescu; Esmaeil Nikfekr; Jonathan Evans; Cris S Constantinescu; Akram A Hosseini
Journal:  Front Neurol       Date:  2021-02-19       Impact factor: 4.086

Review 7.  Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic.

Authors:  Kelvin Kai-Wang To; Siddharth Sridhar; Kelvin Hei-Yeung Chiu; Derek Ling-Lung Hung; Xin Li; Ivan Fan-Ngai Hung; Anthony Raymond Tam; Tom Wai-Hin Chung; Jasper Fuk-Woo Chan; Anna Jian-Xia Zhang; Vincent Chi-Chung Cheng; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

8.  Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies.

Authors:  Sally Esmail; Michael J Knauer; Husam Abdoh; Courtney Voss; Benjamin Chin-Yee; Peter Stogios; Almagul Seitova; Ashley Hutchinson; Farhad Yusifov; Tatiana Skarina; Elena Evdokimova; Suzanne Ackloo; Lori Lowes; Benjamin D Hedley; Vipin Bhayana; Ian Chin-Yee; Shawn S-C Li
Journal:  Cell Rep Methods       Date:  2021-05-12

9.  Cost effective reproduction number based strategies for reducing deaths from COVID-19.

Authors:  Christopher Thron; Vianney Mbazumutima; Luis V Tamayo; Léonard Todjihounde
Journal:  J Math Ind       Date:  2021-06-28

10.  Over- and under-estimation of COVID-19 deaths.

Authors:  John P A Ioannidis
Journal:  Eur J Epidemiol       Date:  2021-07-28       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.